Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

Melissa W. Ko; Madhura A. Tamhankar; Nicholas J. Volpe; David Porter; Cindy McGrath; Steven L. Galetta

doi:10.1016/j.jns.2008.06.028

Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

Melissa W. Ko^*, Madhura A. Tamhankar, Nicholas J. Volpe, David Porter, Cindy McGrath, Steven L. Galetta

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.

Original language	English (US)
Pages (from-to)	144-147
Number of pages	4
Journal	Journal of the Neurological Sciences
Volume	273
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jns.2008.06.028
State	Published - Oct 15 2008

Keywords

Acute promyelocytic leukemia
Mitoxantrone
Multiple sclerosis
Optic nerve

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.jns.2008.06.028

Cite this

@article{4bcb4c707e12483499aad2ddbcb5a67c,

title = "Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis",

abstract = "Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.",

keywords = "Acute promyelocytic leukemia, Mitoxantrone, Multiple sclerosis, Optic nerve",

author = "Ko, {Melissa W.} and Tamhankar, {Madhura A.} and Volpe, {Nicholas J.} and David Porter and Cindy McGrath and Galetta, {Steven L.}",

year = "2008",

month = oct,

day = "15",

doi = "10.1016/j.jns.2008.06.028",

language = "English (US)",

volume = "273",

pages = "144--147",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier B.V.",

number = "1-2",

}

TY - JOUR

T1 - Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

AU - Ko, Melissa W.

AU - Tamhankar, Madhura A.

AU - Volpe, Nicholas J.

AU - Porter, David

AU - McGrath, Cindy

AU - Galetta, Steven L.

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.

AB - Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.

KW - Acute promyelocytic leukemia

KW - Mitoxantrone

KW - Multiple sclerosis

KW - Optic nerve

UR - http://www.scopus.com/inward/record.url?scp=50049104995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049104995&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2008.06.028

DO - 10.1016/j.jns.2008.06.028

M3 - Article

C2 - 18687447

AN - SCOPUS:50049104995

SN - 0022-510X

VL - 273

SP - 144

EP - 147

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this